iTeos Therapeutics (NASDAQ:ITOS – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Profitability

This table compares iTeos Therapeutics and Vigil Neuroscience's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations for iTeos Therapeutics and Vigil Neuroscience, as provided by MarketBeat.com.

Valuation & Earnings

This table compares iTeos Therapeutics and Vigil Neuroscience's revenue, earnings per share (EPS) and valuation.

iTeos Therapeutics has higher revenue and earnings than Vigil Neuroscience. Vigil Neuroscience is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

88.9% of Vigil Neuroscience shares are held by institutional investors. 6.5% of iTeos Therapeutics shares are held by insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

iTeos Therapeutics beats Vigil Neuroscience on 7 of the 11 factors compared between the two stocks.

About iTeos Therapeutics

(Get Rating)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

About Vigil Neuroscience

(Get Rating)

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.